The dual kinase complex FAK-src as a promising therapeutic target in cancer

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 83-97

  Bolós, Victoria ^a   Gasent, Joan Manuel ^b   López Tarruella, Sara ^c   Grande, Enrique ^a,d  

^a PFIZER INC   (United States)

^b Hospital Gral Universitario Marina Alta   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cancer; FAK; FAK inhibitors; SRC; SRC inhibitors; Therapeutic target

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; ANGIOGENESIS INHIBITOR; BOSUTINIB; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; FOCAL ADHESION KINASE RELATED NONKINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; INTEGRIN; PF 562271; PROTEIN KINASE; PROTEIN KINASE P60; PROTEIN P53; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SCATTER FACTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; STEROID RECEPTOR COACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANOIKIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FATIGUE; FOCAL ADHESION; HUMAN; MONOTHERAPY; NAUSEA; NONHUMAN; ONCOGENE SRC; OVARY CANCER; PANCREAS CANCER; PHILADELPHIA 1 CHROMOSOME; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SKIN CANCER; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; VOMITING; WEIGHT REDUCTION;

EID: 79955727135     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/ott.s6909     Document Type: Review

References (157)

1. Guo W, Giaconti FG. Integrin signaling during tumor progression. Nat Rev Mol Cell Biol. 2004;5(10):816-826
2. Calalb MB, Polte TR, Hanks SK. Tyrosine of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995;15:954-963
3. Satyajit K Mitra, David D Schlaepfer. Integrin-regulated FAK-Src signaling in normal and cancer cells. Current Opinion in Cell Biology. 2006;18(5):516-523
4. Bruton VG, MacPherson IRJ, Frame MC. Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim Biophys Acta. 2004;1692:121-144
5. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene. 2004;18;23(48): 7928-7946
6. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 2009;69(2):475-478
7. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene.2004;23(48): 7957-7968
8. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814-2823
9. Van Nimwegen MJ, Van Dewater B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol. 2007;73:597-609
10. Morgan L, Nicholson RI, Hiscox S. SRC as a therapeutic target in breast cancer. Endocr Metab Immune Disord Drug Targets. 2008;8(4):273-278
11. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 2008;14(3):627-632
12. Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008;19(8): 1379-1386
13. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biological Chem. 2007;282(20):14845-14852
14. Jarkowski A, Sweeney RP. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy. 2008;28(11):1374-1382
15. Siu LL, et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. Abstract 3527 2007 ASCO Annual Meeting. Chicago, IL, USA.
16. Siu LL, et al. A phase I clinical, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with advanced solid tumors. Abstract 3534 2008 ASCO Annual Meeting. Chicago, IL, USA.
17. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). Abstract 5061 2009 ASCO Annual Meeting. Chicago, IL, USA.
18. Kluger HM, Dudek A, McCann C, et al. A phase II trial of dasatinib inadvanced melanoma. Abstract 9010 2009 ASCO Annual Meeting. Chicago, IL, USA.
19. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. Abstract 1011 2009 ASCO Annual Meeting. Chicago, IL, USA.
20. Rous PA. Transmission of a malignant new growth by means of a cell-free filtrate. JAMA. 1911;56:198-202
21. Rous PA. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911;13(4):397-411
22. Steven Martin G. The hunting of the Src. Nature Rev Molec Cell Biol. 2001;2:467-475
23. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6): 470-480
24. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta. 2008; 1784(1):56-65
25. Cox BD, Natarajan M, Stettner MR, Gladson CL. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006;99(1):35-52
26. Kanner SB, et al. Monoclonal antibodies to individual tyrosinephosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci. 1990:87(9):3328-3332
27. Shaller MD, Borgman CA, Cobb BS, et al. Pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci. 1992;89:5192-5196
28. Schaller MD, Parsons JT: Focal adhesion kinase and associated proteins. Curr Opin Cell Biol. 1994;6:705-771
29. Brunton VG, Avizienyte E, Fincham VJ, et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res. 2005;65(4):1335-1342
30. Avizienyte E, Wyke AW, Jones RJ, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling. Nat Cell Biol. 2002;4(8):632-638
31. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2(5):249-256
32. Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol. 2002;157(1):149-160
33. Schaller MD, Borgman CA, Parsons JT. Autonomous expression of a noncatalytic domain of the focal adhesion associated protein tyrosine kinase pp.125FAK. Mol Cell Biol. 1993;13:785-791
34. Mitra SK, Schaepfer DD. Integrin-regulated FAK-C-src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516-523
35. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009;28(1-2):35-49
36. Parsons JT, Martin KH, Slack JK, Taylor JM. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19(49):5606-5613
37. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358
38. Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995;377:539-544
39. Peng X, Ueda H, Zhou H, et al. Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovascular Res. 2004;64:421-430
40. Weis SM, Lim ST, Lutu-Fuga KM, et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell. FAK. J Cell Biol. 2008;181:43-50
41. Guinamard R, Okigaki M, Schlessinger J, Ravetich JV. Absence of marginal zone B cell in Pyk2-deficient mice defines their role in the humoral response. Nat Immunol. 2000;1:31-36
42. Okigaki M, Davis C, Falasca M, et al. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Nat Acad Sci. 2003;100:10740-10745
43. Lim ST, Chen XL, Lim Y, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29(1):9-22
44. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64(4):693-702
45. Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664
46. Rucci N, Susa M, Teti. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem. 2008;8(3):342-349
47. Zhan M, Zhao H, Han ZC. Signaling mechanisms of anoikis. Histol Histopathol. 2004;19(3):973-983
48. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery. 2004;135(5):555-562
49. Liu G, Meng X, Jin Y, et al. Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549. Cell Biol Int. 2008;32(6):663-670
50. Díaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer. 2006;42(10):1491-500
51. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003;22(4):359-374
52. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer. 2005;113(3):372-378
53. Recher C, Ysebaert L, Beyne-Rauzy O, et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 2004;64(9):3191-3197
54. Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ.
55. Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer. 2003;13(5):640-646
56. Ding J, Li D, Wang X, Wang C, Wu T. Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell. Hepatogastroenterology. 2008;55(88):2072-2076
57. Panta GR, Nwariaku F, Kim LT. RET signals through focal adhesion kinase in medullary thyroid cancer cells. Surgery. 2004;136(6):1212-1217
58. Panta GR, Du L, Nwariaku FE, Kim LT. Direct phosphorylation of proliferative and survival pathway proteins by RET. Surgery. 2005;138(2):269-274
59. Tong Z, Kunnumakkara AB, Wang H, et al. Neutrophil gelatinaseassociated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. S Cancer Res. 2008;68(15):6100-6108
60. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6(4): 1357-1367
61. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94(6):2199-2203
62. Chen J. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):306-307
63. Haskell H, Natarajan M, Hecker TP, et al. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin Cancer Res. 2003;9(6):2157-2165
64. Angelucci A, Bologna M. Curr. Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family. Pharm Des. 2007;13(21):2129-2145
65. Earley S, Plopper E. Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells. Biochem Biophys Res Commun. 2006;350:405-412
66. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for C-src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 1999;4:915-924
67. Niu G, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-2008
68. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res. 2003;291: 70-82
69. Laird AD, et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells. Mol Cancer Ther. 2003;2:461-469
70. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth Factor. J Natl Cancer Inst. 2000;92(13):1065-1073
71. Cascone I, Napione L, Maniero F, Serini G, Bussolino FJ. Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. Cell Biol. 2005;170(6):993-1004
72. Halder J, Landen CN Jr, Lutgendorf SK, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005;11(24 Pt 1):8829-8836
73. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003;311(3):786-792
74. Ischenko I, Camaj P, Seeliger H, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene. 2008;27(57):7212-7222
75. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10(7):2307-2318
76. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Sirna directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg. 2004;198(6):953-959
77. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs. 2007;18(4):371-375
78. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088; Abstract: 1011
79. ASCO Annual Meeting, Chicago IL, USA. 79. Gutenberg A, Brück W, Buchfelder M, Ludwig HC. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol. 2004;108(3):224-230
80. Behmoaram E, Bijian K, Jie S, et al. Focal adhesion kinase-related proline- rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008;173(5):1540-1550
81. Sun CK, Ng KT, Sun BS, et al. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer. 2007;97(1):50-57
82. Iiizumi M, Bandyopadhyay S, Pai SK, et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res. 2008;68(18):7613-7620
83. Zhang S, Qiu X, Gu Y, Wang E. Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. Lung Cancer. 2008;62(3): 295-301
84. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem. 2007;7(6):651-659
85. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15(6):740-746
86. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-428
87. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat. 2008;11(4-5):123-151
88. Bailey KM, Liu JJ. Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. Biol Chem. 2008;283(20):13714-13724
89. Cicchini C, Laudadio I, Citarella F, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008;314(1):143-152
90. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008;112(9):2088-2100
91. Wei J, Xu G, Wu M, et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008;28(1A):327-334
92. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro- 6methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5 carboxamide (BMS-354825),a dual Src/Abl. kinase inhibitor with potent antitumor activityin pre-clinical assays. J Med Chem. 2004; 47(27):6658-6661
93. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006 1;66(11):5790-5797
94. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res. 2007;13(24): 7232-7236
95. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105(3): 319-326
96. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67(5):2226-2238
97. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse mode. Cancer Res. 2008;68(9):3323-3333
98. Xiao-Feng Le, Weiqun Mao, Zhen Lu, Robert C Bast Jr. Dasatinib induces autophagy as well as growth arrest in human ovarian cancer cells. Abstract 388. AACR 2009
99. Tryfonopoulos D, O'Donovan N, Corkery B, Clynes M, Crown J. Activity of dasatinib with chemotherapy in triple-negative breast cancer cells. Abstract: e14605 2009 ASCO Annual Meeting, Chicago, IL, USA.
100. Seoane S, Montero JC, Pandiella A, Ocana A. Effect of dasatinib on the activity of trastuzumab in HER2- overexpressing breast cancer cells; Abstract: 1084 2009 ASCO Annual Meeting, Chicago, IL, USA.
101. Hennequin LF, Allen J, Breed J, et al. N-(5-chloro-1,3-benzodioxol- 4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2Hpyran- 4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Med Chem. 2006;49(22):6465-6488
102. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2006;97:263-274
103. Hiscox S, Jordan NJ, Smith C, et al. Dual targeting of Src and ER prevent acquired antihormone resistance in breast cells. Breast Cancer Res Treat. 2009;115(1):57-67
104. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors. Clin Cancer Res. 2009;15(10):3396-3405
105. Herynk MH, Beyer AR, Cui Y, et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther. 2006 5(12):3023-3031
106. Clinical Trials.gov. Clinical Trials AZDO530 at: http://www.clinicaltrial. gov/ct2/results?term=AZD0530+ accessed March 2010
107. Stratford IJ, Telfer B, Green TP, et al. Inhibition of metastatic dissemination following loco-regional control of a primary tumor: examining a novel treatment paradigm with the Src kinase inhibitor AZD0530 Abstract 4946. AACR 2009
108. Boschelli DH, Wu B, Ye F. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]- 7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006;49(26): 7868-7876
109. Rabbani SA, Valentino ML, Ali S, Boschelli F. Inhibitor of Src kinase SKI-606 (Bosutinb) blocks prostate cancer growth, invasion and experimental skeletal metastases in vitro and in vivo by regulating the expression of key intracellular signaling molecules and genes involved in prostate cancer progression. Abstract 2325. AACR 2009
110. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.Cancer Res. 2007;67(4): 1580-1588
111. Messersmith WA, Krishnamurthi S, Hewes BA, et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. Abstract 3552 2007 ASCO Annual Meeting. Chicago, IL, USA.
112. Clinical Trials.gov. Clinical Trials Bosutinib at: http://www. clinicaltrial.gov/ct2/results?term=Bosutinib+ accessed March 2010
113. Roberts WG, Ung E, Whalen P, et al. Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271. Cancer Res. 2008;68(6):1935-1944
114. Jayme B, Stokes SJ, Adair JK, et al. Targeting FAK in pancreatic cancer: a novel therapeutic approach. Abstract 843, AACR 2209
115. Bagi CM, Christensen J, Cohen DP, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biology and Therapy. 2009;8(9):856-865
116. Cascone I, Napione L, Maniero F, Serini G, Bussolino FJ. Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. Cell Biol. 2005;170(6):993-1004
117. Bagi CM, Roberts GW, Andresen CJ. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer 2008;112(10):2313-2321
118. Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007;282(20):14845-14852
119. Stone RL, Nick AM, Spannuth W, et al. The clinical and biological significance of focal adhesion kinase activation in ovarian carcinoma. Abstract 3636. AACR 2009
120. Dos Santos LA, et al. The FAK Inhibitor PF573228 Demonstrates Anti-proliferative and anti-invasive activity in MUC16/CA125 ovarian carcinoma cells. Abstract 3519. AACR 2009
121. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007;67(22):10976-10983
122. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis. 2008;29(6):1096-1107
123. Hao H, Wang Z, Bao X, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR survival signaling. Abstract 1840. AACR 2009
124. Ucar D, Kurenova E, Zheng D, et al. A novel small molecule that targets the FAK and IGF-1R site of interaction inhibits growth of human cancer. Abstract 2008. AACR 2009
125. Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol. 2006;101(3):507-519
126. Van Nimwegen MJ, Huigsloot M, Camier A, Tijdens IB, van de Water B. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol. 2006;70(4):1330-1339
127. Kornberg LJ: Adenovirus-mediated transfer of FRNK augments drug-induced cytotoxicity in cultured SCCHN cells. Anticancer Res. 2005;25:4349-4356
128. Fang Y, Wang L, Jin J, et al. Ref Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to TNF- α/cycloheximide-induced apoptosis by regulating protein kinase B levels. Eur J Biochem. 2001;268:4513-4519
129. Wu ZM, Yuan XH, Jiang PC, et al. Antisens oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol. 2006;77:117-123
130. Fang Y, Wang L, Jin J, Zha X. Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to TNF-α/cycloheximide-induced apoptosis by regulating protein kinase B levels. Eur J Biochem. 2001;268:4513-4519
131. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006;12(16): 4916-4924
132. Smith CS, Golubovskaya VM, Peck E, et al. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res. 2005;15(5):357-362
133. Somlo G, Atzori F, Strauss L, et al. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. Abstract: 1012 2009 ASCO Annual Meeting, Chicago IL, USA.
134. Teoh D, Ayeni TA, Rubatt JM, et al. In vitrocharacterization of the antitumor effects of dasatinib (BMS-354825) in combination with paclitaxel and carboplatin in human ovarian cancer cell lines. Abstract 828. AACR 2009
135. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006;12(5):1398-1401
136. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog. 1998;21(4):261-272
137. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y. Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem. 2007;282(14):10697-10706
138. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol. 1994;14(1): 735-743
139. Elsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene. 2001;20(12): 1465-1475
140. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett. 2003;543(1-3):76-80
141. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cellderived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005;65(15):6493-6497
142. Ishizawar RC, Miyake T, Parsons SJ. C-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene. 2007;26(24): 3503-3510
143. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab. 2005;16(8):347-353
144. Chu I, Arnaout A, Loiseau S, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest. 2007;117(8):2205-2215
145. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67(5):2226-2238
146. Finn RS, Bengala C, Ibrahim N, et al. Phase II Trial of Dasatinib in Triple-negative Breast Cancer: Results of Study CA180059. SABCS 2008
147. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003;144(3):1032-1044
148. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis. 2004;21(3):201-212
149. Nicholson RI, Hutcheson IR, Harper ME, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptorpositive breast cancer. Ann N Y Acad Sci. 2002;963:104-115
150. Massarweh S, Osborne CK, Jiang S, et al. Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer Cancer Res. 2006;66(16):8266-8273
151. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12): 926-935
152. Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis. 2007;24(3):157-167
153. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun. 2006;341(1):73-81
154. Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol. 2007;60(4):535-543
155. Planas-Silva MD, Waltz PK. Estrogen promotes reversible epithelialto- mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2007;104(1-2): 11-21
156. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors. Clin Cancer Res. 2009;15(10) 3396-3405
157. Campbell EJ, McDuff E, Tatarov O, et al. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer. 2008 Dec 2;99(11):1769-1774.